Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-08 |
2024-03 |
-0.21 |
-0.23 |
-0.02 |
-9.52% |
2024-03-27 |
2023-12 |
-0.24 |
N/A |
N/A |
N/A |
2024-03-27 |
2023-12 |
-0.24 |
-0.2 |
0.04 |
16.67% |
2023-11-09 |
2023-09 |
-0.21 |
-0.2 |
0.01 |
4.76% |
2023-11-09 |
2023-09 |
-0.21 |
N/A |
N/A |
N/A |
2023-08-10 |
2023-06 |
-0.27 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-10-10 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2023-06-05 |
Mizuho |
Upgrade |
Buy |
Buy |
2023-06-05 |
Evercore ISI Group |
Upgrade |
Outperform |
Outperform |
2023-05-15 |
Goldman Sachs |
Upgrade |
Buy |
Buy |
2023-03-29 |
Mizuho |
Upgrade |
|
Buy |
2023-02-23 |
Goldman Sachs |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2021-07-19 |
ARCH VENTURE PARTNERS X LLC |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Conversion of Exercise of derivative security |
2022-12-20 |
BRISTOL JAMES ARTHUR |
Director |
0.00 |
Purchase |
2023-12-03 |
CASDIN ALEXANDER W |
Director |
587.72K |
Purchase |
2022-12-12 |
CHEN BIHUA X. |
Director |
0.00 |
Purchase |
2021-07-19 |
GARNER EBUN S |
General Counsel |
900.00 |
Purchase |
2021-07-19 |
HAMBLETON JULIE |
Director |
6.00K |
Purchase |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Arch Venture Management, Llc |
11.06M |
30.51M |
7.32% |
2023-06-29 |
Cormorant Asset Management, LP |
10.81M |
29.84M |
7.16% |
2023-06-29 |
Armistice Capital, LLC |
7.86M |
21.68M |
5.20% |
2023-06-29 |
Blackrock Inc. |
6.92M |
19.09M |
4.58% |
2023-06-29 |
Vanguard Group Inc |
6.62M |
18.28M |
4.38% |
2023-06-29 |
Pfm Health Sciences, Lp |
4.80M |
13.24M |
3.18% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Small-Cap Index Fund |
1.95M |
5.37M |
1.29% |
2023-08-30 |
iShares Russell 2000 ETF |
1.87M |
4.85M |
1.24% |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
1.83M |
5.05M |
1.21% |
2023-06-29 |
Vanguard Small-Cap Growth Index Fund |
1.11M |
3.08M |
0.74% |
2023-06-29 |
Vanguard Extended Market Index Fund |
969.74K |
2.68M |
0.64% |
2023-08-30 |
iShares Russell 2000 Value ETF |
751.39K |
1.95M |
0.50% |